Tagoor Lab Vildagliptin Tagoor Lab Vildagliptin

X
menu

    Market Place

    Market Place

    Post Enquiry

    Post Enquiry
    menu
    [{"orgOrder":0,"company":"Glenmark Pharmaceuticals","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Glenmark Becomes the First Company to Launch Remogliflozin + Vildagliptin fixed Dose Combination, at an Affordable Price for T2 Dminn India","therapeuticArea":"Endocrinology","highestDevelopmentStatus":"Approved","country":"INDIA","productType":"Small molecule","productStatus":"Approved","date":"December 2020","url1":"","url2":"","graph1":"Endocrinology","graph2":"Approved"},{"orgOrder":0,"company":"Glenmark Pharmaceuticals","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Glenmark Becomes the First Company to Launch Remogliflozin + Vildagliptin + Metformin Fixed Dose Combination, at An Affordable Price for Adults with Type 2 Diabetes in India","therapeuticArea":"Endocrinology","highestDevelopmentStatus":"Approved","country":"INDIA","productType":"Small molecule","productStatus":"Approved","date":"October 2021","url1":"","url2":"","graph1":"Endocrinology","graph2":"Approved"},{"orgOrder":0,"company":"Novartis Pharmaceuticals Corporation","sponsor":"Cipla","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"Cipla Signs Agreement with Novartis for Diabetes Therapy Galvus Range","therapeuticArea":"Endocrinology","highestDevelopmentStatus":"Approved","country":"SWITZERLAND","productType":"Small molecule","productStatus":"Approved","date":"April 2023","url1":"","url2":"","graph1":"Endocrinology","graph2":"Approved"},{"orgOrder":0,"company":"Novartis Pharmaceuticals Corporation","sponsor":"USV Private Limited","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"Supplier can only Seek Advance Ruling under GST, Rules MAAR","therapeuticArea":"Endocrinology","highestDevelopmentStatus":"Approved","country":"SWITZERLAND","productType":"Small molecule","productStatus":"Approved","date":"October 2021","url1":"","url2":"","graph1":"Endocrinology","graph2":"Approved"},{"orgOrder":0,"company":"USV Private Limited","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"USV Launches Jalra Trio for Management of Type 2 Diabetes in India","therapeuticArea":"Endocrinology","highestDevelopmentStatus":"Approved","country":"INDIA","productType":"Small molecule","productStatus":"Approved","date":"August 2023","url1":"","url2":"","graph1":"Endocrinology","graph2":"Approved"},{"orgOrder":0,"company":"USV Private Limited","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"USV Launches Pioz-V for Uncontrolled Diabetic Patients with Fatty Liver","therapeuticArea":"Endocrinology","highestDevelopmentStatus":"Approved","country":"INDIA","productType":"Small molecule","productStatus":"Approved","date":"April 2023","url1":"","url2":"","graph1":"Endocrinology","graph2":"Approved"}]

    Find Clinical Drug Pipeline Developments & Deals for Xiliarx

    Menu

    Xiliarx

    APIs // Active Pharmaceutical Ingredients

    DEVELOPMENTS

    PRICE INFORMATION

    INTERMEDIATES

    DOSSIERs // Finished Dosage Forms

    GLOBAL SALES INFORMATION

    MARKET PLACE

    REF. STANDARDS & IMPURITIES

    DIGITAL CONTENT

    PharmaCompass
    Loading...

    All Data

    Previous
    Next
    Filters Filter
    ×
    FILTER:
    filter Company
      filter Sponsor
        filter Country
          filter Therapeutic Area
            filter Study Phase

              Active Filter(s):

              refreshFilters
              refreshReset Filter
              refresh Reset Filter
              price-trend All Developments

              Companies By Therapeutic Area

              Development Status

              USV Private Limited

              Contact Supplier
              • Development Update
              Virtual BoothUSV offers custom peptide synthesis ranging from gram to multi-gram to multi-kilogram quantities.
              Contact Supplier Contact Supplier
              Flag India
              Virtual Booth Virtual Booth
              Digital Content Digital Content

              USV Launches Jalra Trio for Management of Type 2 Diabetes in India

              Details:

              Jalra-Trio (vildagliptin + dapagliflozin + metformin) is a fixed dose combination medicine that helps control blood sugar levels. It is now approved for the treatment of type-2-diabetes mellitus.

              Lead Product(s): Vildagliptin,Dapagliflozin,Metformin

              Therapeutic Area: Endocrinology Product Name: Jalra Trio

              Highest Development Status: Approved Product Type: Small molecule

              Partner/Sponsor/Collaborator: Not Applicable

              Deal Size: Not Applicable Upfront Cash: Not Applicable

              Deal Type: Not Applicable August 11, 2023

              USV Private Limited

              CPhI Worldwide, Milan

              Booth #10F41

              envelop Contact Supplier

              USV Private Limited

              Contact Supplier
              • Development Update
              Virtual BoothUSV offers custom peptide synthesis ranging from gram to multi-gram to multi-kilogram quantities.
              Contact Supplier Contact Supplier
              Flag India
              Virtual Booth Virtual Booth
              Digital Content Digital Content

              USV Launches Pioz-V for Uncontrolled Diabetic Patients with Fatty Liver

              Details:

              Pioz V (vildagliptin + pioglitazone) is a fixed dose combination medicine that helps control blood sugar levels. It is now approved for the treatment of type-2-diabetes mellitus.

              Lead Product(s): Vildagliptin,Pioglitazone

              Therapeutic Area: Endocrinology Product Name: Pioz V

              Highest Development Status: Approved Product Type: Small molecule

              Partner/Sponsor/Collaborator: Not Applicable

              Deal Size: Not Applicable Upfront Cash: Not Applicable

              Deal Type: Not Applicable April 25, 2023

              USV Private Limited

              CPhI Worldwide, Milan

              Booth #10F41

              envelop Contact Supplier

              Novartis Pharmaceuticals Corporation

              Contact Supplier
              • Deals
              Virtual Booth Upload your Marketing & Sales content on your company Virtual Booth, click HERE
              Post an Enquiry Post an Enquiry
              Flag Switzerland
              Virtual Booth Virtual Booth
              Digital Content Digital Content

              Cipla Signs Agreement with Novartis for Diabetes Therapy Galvus Range

              Details:

              Under the terms of the agreement, Cipla will manufacture and market Galvus (vildagliptin) and Galvus combination brands, used in the treatment of type 2 diabetes.

              Lead Product(s): Vildagliptin

              Therapeutic Area: Endocrinology Product Name: Galvus

              Highest Development Status: Approved Product Type: Small molecule

              Partner/Sponsor/Collaborator: Cipla

              Deal Size: Undisclosed Upfront Cash: Undisclosed

              Deal Type: Agreement April 11, 2023

              ASK
              US
              PHARMACOMPASS
              Upload
              your Pipeline Activity

              Glenmark Pharmaceuticals

              Contact Supplier
              • Development Update
              Virtual Booth Upload your Marketing & Sales content on your company Virtual Booth, click HERE
              Post an Enquiry Post an Enquiry
              Flag India
              Virtual Booth Virtual Booth
              Digital Content Digital Content

              Glenmark Becomes the First Company to Launch Remogliflozin + Vildagliptin + Metformin Fixed Dose Combination, at An Affordable Price for Adults with Type 2 Diabetes in Indi...

              Details:

              Glenmark is the first company in the world to launch Remogliflozin + Vildagliptin + Metformin fixed dose combination (FDC) and India is the first country to get access to this FDC drug.

              Lead Product(s): Remogliflozin Etabonate,Vildagliptin,Metformin

              Therapeutic Area: Endocrinology Product Name: Remozen MV

              Highest Development Status: Approved Product Type: Small molecule

              Partner/Sponsor/Collaborator: Not Applicable

              Deal Size: Not Applicable Upfront Cash: Not Applicable

              Deal Type: Not Applicable October 26, 2021

              ASK
              US
              PHARMACOMPASS
              Upload
              your Pipeline Activity

              Novartis Pharmaceuticals Corporation

              Contact Supplier
              • Deals
              Virtual Booth Upload your Marketing & Sales content on your company Virtual Booth, click HERE
              Post an Enquiry Post an Enquiry
              Flag Switzerland
              Virtual Booth Virtual Booth
              Digital Content Digital Content

              Supplier can only Seek Advance Ruling under GST, Rules MAAR

              Details:

              Under the agreement, USV acquires the trademark for antidiabetes drug Jalra (vildagliptin) and Jalra M (vildagliptin and metformin), used to treat type 2 diabetes mellitus, from Novartis.

              Lead Product(s): Vildagliptin

              Therapeutic Area: Endocrinology Product Name: Jalra

              Highest Development Status: Approved Product Type: Small molecule

              Partner/Sponsor/Collaborator: USV Private Limited

              Deal Size: Undisclosed Upfront Cash: Undisclosed

              Deal Type: Agreement October 22, 2021

              ASK
              US
              PHARMACOMPASS
              Upload
              your Pipeline Activity

              Glenmark Pharmaceuticals

              Contact Supplier
              • Development Update
              Virtual Booth Upload your Marketing & Sales content on your company Virtual Booth, click HERE
              Post an Enquiry Post an Enquiry
              Flag India
              Virtual Booth Virtual Booth
              Digital Content Digital Content

              Glenmark Becomes the First Company to Launch Remogliflozin + Vildagliptin fixed Dose Combination, at an Affordable Price for T2 Dminn India

              Details:

              Glenmark is the first company in the world to launch Remogliflozin (100 mg) + Vildagliptin (50 mg) Fixed Dose Combination. The FDC will be marketed under two brand names Remo V and Remozen V.

              Lead Product(s): Remogliflozin Etabonate,Vildagliptin

              Therapeutic Area: Endocrinology Product Name: Remozen V

              Highest Development Status: Approved Product Type: Small molecule

              Partner/Sponsor/Collaborator: Not Applicable

              Deal Size: Not Applicable Upfront Cash: Not Applicable

              Deal Type: Not Applicable December 29, 2020

              ASK
              US
              PHARMACOMPASS
              Upload
              your Pipeline Activity
              Inke S.A: APIs manufacturing plant.
              ChemWerth works in generic API development & supply, non-infringement patent strategy development and regulatory support.
              Post Enquiry
              POST ENQUIRY